Increased androgen receptor (AR) activity drives therapeutic resistance in advanced
prostate cancer. The most common resistance mechanism is amplification of this locus …

Prostate cancer treatment is dominated by strategies to control androgen receptor (AR)
activity. AR has an impact on prostate cancer development through the regulation of not only …

Purpose Despite treatments which lower circulating androgens, advanced prostate cancers
often maintain androgen receptor (AR) signaling. The variable response to secondary …

Suppression of androgen production and function provides palliation but not cure in men
with prostate cancer (PCa). Therapeutic failure and progression to hormone-refractory PCa …

The standard systemic treatment for prostate cancer (PCa) is androgen ablation, which
causes tumor regression by inhibiting activity of the androgen receptor (AR). Invariably, PCa …

The androgen-signaling pathway is critical to the development and progression of prostate
cancer and androgen ablation is a mainstay of therapy for this disease. We performed a …

The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …

The transcriptional activity of the androgen receptor (AR) is not only critical for the normal
development and function of the prostate but also pivotal to the onset and progression of …

The androgen receptor (AR) regulates prostate cell growth in man, and prostate cancer is
the commonest cancer in men in the UK. We present a comprehensive analysis of AR …

The androgen receptor (AR) is a ligand-inducible transcription factor that mediates
androgen action in target tissues. Upon ligand binding, the AR binds to thousands of …